Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science)

N/A

Report date: 2026/02/10 20:00:22

Base Information

Drug NameAutologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science)

Drug Alias NameGenetically modified HSPCs自体CD34 +富集造血干细胞和祖细胞-Genenta ScienceInterferon alpha 2 gene therapyAutologous CD34+ cell enriched haematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding for human Interferon-alpha2 cDNA (Temferon)Temferon

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionInterferon alpha-2 stimulants

TargetsInterferon alpha-2

Therapy Area/IndicationsMultiple MyelomaCarcinoma, Renal CellGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGenenta Science Srl

China Registration ClassN/A

Develop Information

Active CompaniesGenenta Science Srl

Inactive CompaniesOspedale San Raffaele

Active IndicationsGlioblastoma

Inactive IndicationsMultiple MyelomaCarcinoma, Renal Cell

Other Information

ATC CodeN/A